Internal Reference Number: FOI_6760
Date Request Received: 31/08/2022 00:00:00
Date Request Replied To: 20/09/2022 00:00:00
This response was sent via: By Email
Request Summary: Breast Cancer Treatment
Request Category: Private Individuals
| Question Number 1: In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with: • Abemaciclib (Verzenios) + aromatase inhibitor * • Abemaciclib (Verzenios) + Fulvestrant (Faslodex) • Alpelisib (Piqray) + Fulvestrant (Faslodex) • Atezolizumab (Tecentriq)** • Bevacizumab (Avastin) • Eribulin (Halaven) • Everolimus (Afinitor) + Exemestane • Fulvestrant (Faslodex) as a single agent • Gemcitabine + paclitaxel • Herceptin (Trastuzumab) + paclitaxel • Herceptin (Trastuzumab) as a single agent • Lapatinib (Tyverb) • Neratinib (Nerlynx) • Olaparib (Lynparza) • Palbociclib (Ibrance) + aromatase inhibitor* • Palbociclib (Ibrance) + Fulvestrant (Faslodex) • Pertuzumab (Perjeta) + trastuzumab + docetaxel • Ribociclib (Kisqali) + aromatase inhibitor* • Ribociclib (Kisqali) + Fulvestrant (Faslodex) • Talazoparib (Talzenna) • Trastuzumab emtansine (Kadcyla) • Other active systemic anti-cancer therapy ** *aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole **eg. docetaxel, vinorelbine or capecitabine as a single agent | |
| Answer To Question 1: Q. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with: • Abemaciclib (Verzenios) + aromatase inhibitor * <5 • Abemaciclib (Verzenios) + Fulvestrant (Faslodex) <5 • Alpelisib (Piqray) + Fulvestrant (Faslodex) 0 • Atezolizumab (Tecentriq)** 0 • Bevacizumab (Avastin) 0 • Eribulin (Halaven) 5 • Everolimus (Afinitor) + Exemestane <5 • Fulvestrant (Faslodex) as a single agent 0 • Gemcitabine + paclitaxel 0 • Herceptin (Trastuzumab) + paclitaxel 0 • Herceptin (Trastuzumab) as a single agent <5 • Lapatinib (Tyverb) 0 • Neratinib (Nerlynx) <5 • Olaparib (Lynparza) <5 • Palbociclib (Ibrance) + aromatase inhibitor* 35 • Palbociclib (Ibrance) + Fulvestrant (Faslodex) 5 • Pertuzumab (Perjeta) + trastuzumab + docetaxel <5 • Ribociclib (Kisqali) + aromatase inhibitor* 0 • Ribociclib (Kisqali) + Fulvestrant (Faslodex) 0 • Talazoparib (Talzenna) 0 • Trastuzumab emtansine (Kadcyla) <5 • Other active systemic anti-cancer therapy ** 35 *aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole **eg. docetaxel, vinorelbine or capecitabine as a single agent A. No answer made yet | |
| Question Number 2: For the above patients, how many of these received their first ever dose for each product line? | |
| Answer To Question 2: 19 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
